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Background: Two commercially available microneedle rollers with a needle length of 200 μm and 300 μm were
selected to examine the influence of microneedle pretreatment on the percutaneous permeation of four
non-steroidal anti-inflammatory drugs (diclofenac, ibuprofen, ketoprofen, paracetamol) with different
physicochemical drug characteristics in Franz-type diffusion cells. Samples of the receptor fluids were taken at
predefined times over 6 hours and were analysed by UV–VIS high-performance liquid-chromatography. Histological
examinations after methylene blue application were additionally performed to gather information about barrier
disruption.
Results: Despite no visible pores in the stratum corneum, the microneedle pretreatment resulted in a twofold
(200 μm) and threefold higher (300 μm) flux through the pretreated skin samples compared to untreated skin
samples for ibuprofen and ketoprofen (LogKow> 3, melting point< 100°C). The flux of the hydrophilic compounds
diclofenac and paracetamol (logKow< 1, melting point> 100°C) increased their amount by four (200 μm) to eight
(300 μm), respectively.
Conclusion: Commercially available microneedle rollers with 200–300 μm long needles enhance the drug delivery
of topically applied non-steroidal anti-inflammatory drugs and represent a valuable tool for percutaneous
permeation enhancement particularly for substances with poor permeability due to a hydrophilic nature and high
melting points.
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In vitro permeation study, Physical penetration enhancementBackground
The topical transdermal administration of systemically
active drugs represents a convenient alternative to sys-
temic administration via oral route in both humans and
animals with many advantages like the avoidance of the
first-pass hepatic metabolism, enzymatic degradation
and side effects in the gastro-intestinal tract. The out-
most layer of the epidermis, the stratum corneum, plays
a key role in the skin barrier concerning the intrusion of
foreign substances from the environment and transepi-
dermal water loss (TEWL) [1]. It is composed of keratin
containing corneocytes embedded in a lipid rich matrix,* Correspondence: xjessica.stahl@tihoannover.de
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reproduction in any medium, provided the orwhich acts like a kit-substance and mainly comprises
ceramides, free fatty acids and cholesterol [2]. Sub-
stances applied onto the skin surface, thereby, can pass
this complex structure by different routes. Although the
tortuous pathway between the corneocytes is likely to be
the main route through the stratum corneum, it can be
bypassed by orifices and glands, both of which can ac-
count for a large part of the body surface [1]. However,
transdermal drug delivery is severely limited to a small
percentage of drugs due to physicochemical drug char-
acteristics and barrier properties of the skin. Therefore,
considerable effort has been put into the development of
sophisticated new transdermal drug delivery systems to
overcome the skin barrier. Besides chemical permeation
enhancers [3] and electrical techniques of enhancement
like iontophoresis and electroporation [4-6], systems liketd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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convenient and effective transdermal drug delivery [7].
Microneedle technology has been established to perfor-
ate the skin barrier without inducing pain or bleeding,
as the needles are too short to stimulate the nerves and
to damage blood vessels in the dermis [8,9]. The needles
are made of silicon, glass, metal, polymers or sugar with
sizes ranging from sub-micron to millimetres to form
microscopic holes that allow enhanced drug delivery
[10]. Unlike skin abrasion the microneedle application
represents a safe, efficient and controllable alternative
for increasing transdermal drug delivery [11].
Over the past few years, four different designs such as
“poke and patch” [12], “coat and poke”, “poke and re-
lease” [13,14], and “poke and flow” [15] have been fabri-
cated which have already been established for
macromolecules like insulin or vaccines [9,12].
The easiest approach of using microneedles is to em-
ploy solid microneedles to form a pore in the skin,
through which compounds can pass out of the topical
formulation [16]. Therefore, two different techniques are
disposable: Firstly, solid microneedle arrays are pressed
onto the skin or scraped on the skin and secondly, roll-
ers with attached microscopic needles are rolled over
the skin. The pores produced by either method are alike,
whereby the rollers are easier to use [17]. In vitro exami-
nations with solid microneedles have increased skin per-
meability for substances ranging from nanomaterials to
proteins [12,18] concurrent with an increase in the
TEWL [10,19].
In the present study, two commercially available micro-
needle rollers with different needle lengths (200 μm and
300 μm) were utilised with the aim to determine the effi-
ciency of skin perforation and to describe their influence
on the permeation of several topically applied non-
steroidal anti-inflammatory drugs with different physico-
chemical drug characteristics in an in vitro setup. More-
over, histological staining was performed to characterise




All reagents used in the present study were of the highest
purity available. Diclofenac (molecular weight (MW):
296 g/mol, logKo/w: 0.7, melting point (MP): 284°C), keto-
profen (MW: 254 g/mol, logKo/w: 1.8, MP: 94°C), ibupro-
fen (MW: 206 g/mol, logKo/w: 3.97, MP: 76°C), and
paracetamol (acetaminophen; MW: 151 g/mol, logKo/w:
0.46, MP: 170°C) [20] were obtained from Sigma-Aldrich
(Steinheim, Germany). Methanol was purchased from
Applichem GmbH (Darmstadt, Germany). All other
reagents were obtained from Merck (Darmstadt,
Germany).Animal skin
The skin was obtained from bovine udders, all of which
were harvested from Holstein Friesian cows which died
at a slaughterhouse for food production, and the cleaned
skin samples were stored at - 20°C until use. After thaw-
ing at room temperature split skin samples with a thick-
ness of 600 μm±50 μm were produced using an
electrical microtome (Zimmer, Eschbach, Germany),
whereby damaged skin samples were excluded from the
study [21].
Skin perforation by microneedles
Two different microneedle rollers were used (200 μm
needle length and 300 μm needle length), both of which
possessed of 192 titanium needles (Medik8, London,
United Kingdom, Figure 1) in a cylindrical arrangement.
Prior to the experiment split skin samples with appropri-
ate size of 2 x 2 cm were incubated in phosphate buf-
fered saline (PBS) for 30 minutes. They were placed on a
styropor panel and fixed with needles beyond the subse-
quent diffusion area of the skin samples before the
microneedle rollers were rolled in four axes radial over
the skin surface (Figure 1 C).
Light microscopy
Visualisation of the produced pores was performed by
light microscopy. The skin samples were treated with
the microneedles as mentioned above and were incu-
bated with saturated methylene blue solution in PBS for
120 minutes. The skin samples were forthwith examined
under the light microscope to count the amount of nee-
dles pores within the diffusion area. Afterwards, they
were frozen and cut in 10 μm thick sections with a
cryostat.
In-vitro permeation
The diffusion experiments were performed in Franz-type
diffusion cells obtained from PermeGear (Riegelsville,
PA, USA) with a receptor chamber of approximately
12 ml and a diffusion area of approximately 1.77 cm².
Sonicated PBS was used as receptor fluid. One ml of the
following 80% saturated solution in PBS was applied
onto the skin samples immediately (within 5 minutes)
after pore production: diclofenac 2.6 mg/ml, ibuprofen
23.4 mg/ml, ketoprofen 2.4 mg/ml, paracetamol
17.5 mg/ml. The donor chambers were covered with
parafilmW (American Can Company, Baltimore, USA)
and were checked for precipitation of the compounds
during the whole experiment. Aliquots were taken from
the receptor fluid and replaced by the same amount of
fresh PBS at 0, 0.5, 1, 2, 4, and 6 hours. Each treatment
(untreated control, 200 μm microneedle, and 300 μm
microneedle) was performed in duplicate per animal
(n = 6).
Figure 1 Microneedle roller. Representative images of the microneedle roller (A) and a 200 μm microneedle (B); C shows the microneedle
roller application procedure.
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The receptor fluid samples (100 μl) were analysed by
high-performance liquid-chromatography, the method-
ology of which has derived from recent studies [22]. The
following components were obtained from Beckman
(Fullerton, CA, USA): autosampler 507, pump 126, and
UV–VIS detector 168. The separation took place on a
reversed phase column (LiChroCART 125–4, LiChro-
spher 100 RP-18e, 5 μm (Merck, Darmstadt, Germany)),
which was maintained at 40°C. The mobile phase con-
sisted of 80% methanol and 20% McIlvaine citrate buffer
(pH 2.2) for both diclofenac and ibuprofen, of 60%
methanol and 40% McIlvaine citrate buffer for ketopro-
fen, and of 15% methanol and 85% McIlvaine citrate buf-
fer for paracetamol. The detection was performed at
282 nm (diclofenac), 238 nm (ibuprofen), 260 nm (keto-
profen) and 245 nm (paracetamol), respectively.
Data analysis
The results of the diffusion experiment are expressed as
mean and standard error. The linear part of the gradient
of the permeation curve (time vs. concentration in
the receptor fluid) represents the maximum flux Jmax
(μg/cm²/h) and is employed to calculate the apparent
permeability coefficient Papp (cm/s) according to Niedorf
et al. 2008 [23]. Differences between control samples
and pretreated skin samples were evaluated by Friedman
test followed by Dunn´s multiple comparison test
(GraphPad Prism 4.01 (GraphPad Software Inc., San
Diego, USA). A 0.05 significance level was adopted.
Results
The microneedle application results in an enhanced per-
meation of all applied compounds compared to un-
treated skin (Figure 2). In skin samples pretreated with
the 300 μm microneedles a significant higher perme-
ation was found than in the untreated skin samples, bywhich the maximum flux (Jmax) and the Papp-value are
up to 3-fold (ketoprofen, ibuprofen) to 7-fold (diclofe-
nac) and 8-fold (paracetamol) higher in the microneedle
treated skin samples (Table 1) and hence result in higher
recoveries after microneedle pretreatment.
The correlation of physicochemical drug characteris-
tics with the enhancement of the permeation reveals that
substances with low lipophilicity (R² = 0.73) and high
melting points (R² = 0.76) benefit from microneedle ap-
plication, while there is no correlation of the micronee-
dle pretreatment to the molecular weight (R² = 0.01).
Although no visible pores are detectable by light mi-
croscopy directly after puncturing the skin, the methy-
lene blue application reveals the existence of barrier
damage after microneedle treatment (Figure 3 A and B),
which is also detectable in histological sections (Figure 3
C and D). The density of the microscopic holes was ap-
proximately 48 pores/cm².
Discussion
In the present study, two commercially available micro-
needle rollers with different needle lengths have been uti-
lised to overcome the natural skin barrier. A staining
method was employed to determine the ability of the
microneedles to invade into the skin, and diffusion experi-
ments with several non-steroidal anti-inflammatory drugs
were performed to investigate the ability of microneedles
to enhance transdermal drug delivery of non-steroidal
anti-inflammatory drugs.
At first, the capability of the microneedle rollers to
disrupt the skin barrier could be confirmed by the blue
staining under the light microscope. Methylene blue is a
dye with a molecular mass of 320 g/mol with a high af-
finity to proteins. The latter characteristic results in the
fact that after application of methylene blue solution
onto physiological intact skin no dye can be found in
deeper skin layers. Thus, the methylene blue staining
Figure 2 Permeation profile. Permeation of diclofenac, ibuprofen, ketoprofen and paracetamol through bovine udder skin samples following
pretreatment with 200 μm and 300 μm microneedles in comparison to untreated control skin (n = 5–6); mean+ SEM.
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ment detectable.
As the needle assembly, the geometry and the velocity
insertion of the microneedles treatment [24] severely in-
fluence the penetration depth and the pore size, a direct
comparison between various types of microneedles should
be made with caution. However, in accordance with
former studies which demonstrated that 150 μm long nee-
dles do not form measurable wholes in the skin [10], the
200 μm and 300 μm needles show similarly manners. As a
result of an in vitro-study, information about pain or
bleeding could not be determined. Since no alterations in
the deeper skin layers have been observed (Figure 3 C and
D), it is likely that the needles used in the present study
can not cause any pain or bleeding, and recent studies in
humans have demonstrated that microneedles were ap-
plied to human skin in a painless manner [8,25].Table 1 Permeation parameters
Diclofenac Ibuprofen
Parameter Control 200 μm 300 μm Control 200 μm 30
Jmax (μg/cm²/h) 1.72 8.75 11.55 167.78 368.69 4
10-6 Papp (cm/s) 0.18 0.93 1.24
* 1.92 4.21 5
Recovery (%) 0.49 3.17 3.54 6.76 11.15 1
Mean permeation parameters following substance application to bovine skin; * = p<Moreover, the ability of microneedles to enhance skin
permeability of non-steroidal anti-inflammatory drugs
was verified by in vitro-diffusion experiments with bo-
vine split skin. The application of two types of micronee-
dles resulted in altered permeation rates for both needle
lengths, yet only the 300 μm-microneedle roller led to a
statistical significant higher permeation rate for all test
compounds. This may be due to the considerable barrier
disruption produced by the 300 μm needles and may be
adjusted by increasing amounts of pores of the 200 μm
needles. However, higher amounts of pores intensify skin
permeability only for a certain extent [26]. For microbio-
logical risk assessment, an in vitro-study has been per-
formed after microneedle administration by Donnelly
et al. 2009 [27]. It has been shown that microneedle
induced holes in the stratum corneum result in signifi-
cant less microbial penetration than hypodermic needlesSubstance
Ketoprofen Paracetamol
0 μm Control 200 μm 300 μm Control 200 μm 300 μm
31.52 1.03 2.36 2.99 2.58 9.97 19.42
.27* 0.12 0.28 0.35* 0.04 0.16 0.31*
7.75 0.30 0.76 0.96 0.14 0.55 1.06
0.05 (microneedle versus control), n = 5–6.
Figure 3 Microneedle treatment. Light microscopic images of bovine skin treated with microneedles of 200 μm (A) and 300 μm (B) needle
lengths after topical administration of methylene blue solution for 6 hours; the arrows show the punctured areas with methylene blue
penetration into deeper skin layers. C and D show histological images of perforated skin samples (C: 200 μm, D: 300 μm) after administration of
methylene blue on the microneedle pretreated skin samples; the arrows show the punctured areas with methylene blue penetration into deeper
skin layers. The bars represent 500 μm.
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after microneedle pretreatment. Thus, it is likely that
microneedle application in an appropriate manner will
not result in either local or systemic infections in
immune-competent individuals as far as the micronee-
dles are manufactured under aseptic or sterile conditions
[27].
Recent in vitro-examinations about permeation en-
hancement of topically applied substances in micronee-
dle treated skin revealed a permeation enhancement up
to 2 times for the hydrophilic acetylsalicylic acid [28],
whereas the previous study demonstrated permeation
enhancements up to 3–8 times depending on the sub-
stance lipophilicity. But it has to be taken into consider-
ation that the manner of application of the needles
complicates a direct comparison between different
examinations as well as the skin type used (full thickness
skin vs. split skin) [10].
In order to obtain information about the influence of
physicochemical drug characteristics on drug enhance-
ment by microneedles, non-steroidal anti-inflammatory
drugs with different molecular weights, lipophilicities
and melting points were chosen. Despite the application
of 80% saturated solutions for each compound, different
levels of permeation enhancement were obtained. In
contrast to a comparative study with different particle
sizes which demonstrated that small sizes were more ef-
fective in drug delivering into the horny layer [10] the
present study did not reveal a correlation betweenpermeation enhancement and molecular weight. How-
ever, a higher permeation enhancement was observed
for more hydrophilic compounds like paracetamol and
diclofenac compared to the lipophilic drugs ibuprofen
and ketoprofen. This may be due to the effect that hydro-
philic substances, that bypass the lipophilic stratum cor-
neum e.g. by a microscopic pore, partition faster into the
hydrophilic skin layers compared to lipophilic compounds
[7,10,29-34]. Once a hydrophilic drug has bypassed the
lipophilic stratum corneum a fast permeation into the re-
ceptor fluid can be assumed, since the dermis does not
represent a distinct barrier for hydrophilic compounds
[35].
Another important physicochemical drug characteris-
tic in transdermal drug delivery is the melting point of
the applied compound [36,37]. Substances with low
melting points exhibit a high solubility in epidermal
lipids, which in turn provides a higher thermodynamic
activity for percutaneous permeation. Hence, it is not
surprising that the present study reveals a higher perme-
ation enhancement for substances with high melting
points (diclofenac and paracetamol), both of which can
bypass the stratum corneum lipids through the pores
produced by the microneedles.
Previous in vivo-investigations performed by Bal et al.
2008 [38] showed that under non occlusive conditions
the pores remained open for a few hours, which can be
enhanced up to 72 hours by performance of occlusive
conditions [39]. Since the present study was conducted
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have been open for the entire experiment. Furthermore,
barrier disruption can result in a fast substance influx
into the deeper skin layer with depot formation. This
depot can release the substance into the blood or lymph-
atic system in vivo.
Conclusion
The present study demonstrates the ability of 200 μm
and 300 μm long microneedles to interrupt the main
skin barrier and to enhance transdermal drug delivery of
topically applied non-steroidal anti-inflammatory drugs
especially with a hydrophilic nature and high melting
points by orders of magnitude. This transdermal delivery
approach is easy to employ, minimally invasive and
represents an appealing method with great potential for
other applications.
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